Brind.

Multiple financial institutions, including Goldman Sachs, Morgan Stanley, Bank of America, UBS, and others, provided ratings and price targets for Marvell Technology on May 28, 2026.

3 reports, 2 independent Updated Aug 28
Gone quiet
Reports
3
Developments
5
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Multiple financial institutions, including Goldman Sachs, Morgan Stanley, Bank of America, UBS, and others, provided ratings and price targets for Marvell Technology on May 28, 2026.

Who's involved

What this event is mainly about
Marvell TechnologyGoldman SachsMorgan StanleyBank of AmericaUBS

How it developed

Newest first. Tap a step to see who reported it.
  1. Ratings firms maintain bullish outlook on Marvell; Google reportedly interested in buying shares.1 source
  2. UBS and Goldman Sachs updated ratings for Marvell Technology, coinciding with CEO insider selling activity.1 source
  3. JPMorgan Chase, Morgan Stanley, UBS, and Bank of America raised price targets for a company, signaling confidence in its future prospects.Sub-event
  4. Financial institutions, including UBS and Deutsche Bank, upgraded Elevance Health to Buy rating on May 28, 2026, while it operates as a health insurer in the United States.Sub-event
  5. Ratings and price targets issued by major banks (GS, MS, BofA, UBS) for Marvell Technology on May 28.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped